Post hoc analyses suggest superior long-term efficacy of ixekizumab.

Risk increase is seen regardless of cardiovascular risk profile.

A thirty-fold increase in Kawasaki-like disease in the last month

The CDC has published a case definition of the Kawasaki-like disease striking children.

Results suggest that an unmet need for better psoriasis treatment.

Long-term analysis supports previous head-to-head data.

Symptom is most common among younger patients.

Leaked CDC document suggests dire mortality outcomes.

Long-term open-label extension shows similar safety as vehicle control.

The findings point to a need for increased screening in patients with rosacea.

No associations with mortality were identified in hospitalized patients with CV disease.

Evidence is very low, and agents should be reserved for clinical trials, they advise.

COVID-19 challenges national unity.

Few trials have assessed the relative efficacy of systemic immunomodulatory treatments.